Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors

Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. Wit...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 63; no. 18; pp. 10287 - 10306
Main Authors Haider, Achi, Gobbi, Luca, Kretz, Julian, Ullmer, Christoph, Brink, Andreas, Honer, Michael, Woltering, Thomas J., Muri, Dieter, Iding, Hans, Bürkler, Markus, Binder, Martin, Bartelmus, Christian, Knuesel, Irene, Pacher, Pal, Herde, Adrienne Müller, Spinelli, Francesco, Ahmed, Hazem, Atz, Kenneth, Keller, Claudia, Weber, Markus, Schibli, Roger, Mu, Linjing, Grether, Uwe, Ametamey, Simon M.
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 24.09.2020
Amer Chemical Soc
Subjects
Animals
Brain - diagnostic imaging
Chemistry, Medicinal
Fluorine Radioisotopes - chemistry
Humans
Life Sciences & Biomedicine
Ligands
Male
Molecular Docking Simulation
Molecular Structure
Pharmacology & Pharmacy
Positron-Emission Tomography
Pyridines - chemical synthesis
Pyridines - pharmacokinetics
Pyridines - pharmacology
Radiopharmaceuticals - chemical synthesis
Radiopharmaceuticals - pharmacokinetics
Radiopharmaceuticals - pharmacology
Rats, Wistar
Receptor, Cannabinoid, CB2 - metabolism
Science & Technology
Spinal Cord - diagnostic imaging
Spleen - diagnostic imaging
Structure-Activity Relationship
Tritium - chemistry
SYSTEM
PET RADIOLIGANDS
CB2 RECEPTORS
PHARMACOLOGY
HIGH-AFFINITY
IN-VIVO EVALUATION
EXPRESSION
BINDING
DISCOVERY
LIPOPHILICITY
Online AccessGet full text

Cover

Abstract Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (K i for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d 6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]­RoSMA-18-d 6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]­RoSMA-18-d 6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]­RoSMA-18-d 6 is a promising CB2 PET radioligand for clinical translation.
AbstractList Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.
Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (K i for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d 6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]­RoSMA-18-d 6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]­RoSMA-18-d 6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]­RoSMA-18-d 6 is a promising CB2 PET radioligand for clinical translation.
Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a subnanomolar affinity (K-i for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d(6) exhibited outstanding in vitro performance characteristics and was radio-fluorinated with an average radiochemical yield of 10.6 +/- 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/mu mol (radiochemical purity > 99%). [F-18]RoSMA-18-d(6) showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [F-18]RoSMA-18-d(6) was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [F-18]RoSMA-18-d(6) is a promising CB2 PET radioligand for clinical translation.
Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity ( for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18- exhibited outstanding performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% ( = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [ F]RoSMA-18- showed exceptional CB2 attributes as demonstrated by autoradiography, biodistribution, and positron emission tomography (PET). Further, [ F]RoSMA-18- was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [ F]RoSMA-18- is a promising CB2 PET radioligand for clinical translation.
Author Muri, Dieter
Herde, Adrienne Müller
Mu, Linjing
Bürkler, Markus
Weber, Markus
Gobbi, Luca
Ullmer, Christoph
Knuesel, Irene
Kretz, Julian
Iding, Hans
Binder, Martin
Honer, Michael
Pacher, Pal
Bartelmus, Christian
Haider, Achi
Brink, Andreas
Spinelli, Francesco
Atz, Kenneth
Keller, Claudia
Woltering, Thomas J.
Grether, Uwe
Schibli, Roger
Ametamey, Simon M.
Ahmed, Hazem
AuthorAffiliation Neuromuscular Diseases Unit/ALS Clinic
Pharma Research and Early Development, Roche Innovation Center Basel
Department of Nuclear Medicine
F. Hoffmann-La Roche
Laboratory of Cardiovascular Physiology and Tissue Injury
ETH Zurich
Pharma Technical Development
National Institute of Health/NIAAA
F. Hoffmann-La Roche Ltd
Institute of Pharmaceutical Sciences
University Hospital Zurich
AuthorAffiliation_xml – sequence: 0
  name: Pharma Research and Early Development, Roche Innovation Center Basel
– sequence: 0
  name: Neuromuscular Diseases Unit/ALS Clinic
– sequence: 0
  name: F. Hoffmann-La Roche
– sequence: 0
  name: Institute of Pharmaceutical Sciences
– sequence: 0
  name: ETH Zurich
– sequence: 0
  name: Laboratory of Cardiovascular Physiology and Tissue Injury
– sequence: 0
  name: Department of Nuclear Medicine
– sequence: 0
  name: F. Hoffmann-La Roche Ltd
– sequence: 0
  name: University Hospital Zurich
– sequence: 0
  name: National Institute of Health/NIAAA
– sequence: 0
  name: Pharma Technical Development
Author_xml – sequence: 1
  givenname: Achi
  orcidid: 0000-0002-5204-4473
  surname: Haider
  fullname: Haider, Achi
  organization: ETH Zurich
– sequence: 2
  givenname: Luca
  orcidid: 0000-0002-0563-2491
  surname: Gobbi
  fullname: Gobbi, Luca
  organization: F. Hoffmann-La Roche
– sequence: 3
  givenname: Julian
  surname: Kretz
  fullname: Kretz, Julian
  organization: F. Hoffmann-La Roche
– sequence: 4
  givenname: Christoph
  surname: Ullmer
  fullname: Ullmer, Christoph
  organization: F. Hoffmann-La Roche
– sequence: 5
  givenname: Andreas
  surname: Brink
  fullname: Brink, Andreas
  organization: F. Hoffmann-La Roche
– sequence: 6
  givenname: Michael
  surname: Honer
  fullname: Honer, Michael
  organization: F. Hoffmann-La Roche
– sequence: 7
  givenname: Thomas J.
  surname: Woltering
  fullname: Woltering, Thomas J.
  organization: F. Hoffmann-La Roche
– sequence: 8
  givenname: Dieter
  surname: Muri
  fullname: Muri, Dieter
  organization: F. Hoffmann-La Roche
– sequence: 9
  givenname: Hans
  surname: Iding
  fullname: Iding, Hans
  organization: F. Hoffmann-La Roche Ltd
– sequence: 10
  givenname: Markus
  surname: Bürkler
  fullname: Bürkler, Markus
  organization: F. Hoffmann-La Roche
– sequence: 11
  givenname: Martin
  surname: Binder
  fullname: Binder, Martin
  organization: F. Hoffmann-La Roche
– sequence: 12
  givenname: Christian
  surname: Bartelmus
  fullname: Bartelmus, Christian
  organization: F. Hoffmann-La Roche
– sequence: 13
  givenname: Irene
  surname: Knuesel
  fullname: Knuesel, Irene
  organization: F. Hoffmann-La Roche
– sequence: 14
  givenname: Pal
  surname: Pacher
  fullname: Pacher, Pal
  organization: National Institute of Health/NIAAA
– sequence: 15
  givenname: Adrienne Müller
  surname: Herde
  fullname: Herde, Adrienne Müller
  organization: ETH Zurich
– sequence: 16
  givenname: Francesco
  surname: Spinelli
  fullname: Spinelli, Francesco
  organization: ETH Zurich
– sequence: 17
  givenname: Hazem
  surname: Ahmed
  fullname: Ahmed, Hazem
  organization: ETH Zurich
– sequence: 18
  givenname: Kenneth
  surname: Atz
  fullname: Atz, Kenneth
  organization: F. Hoffmann-La Roche
– sequence: 19
  givenname: Claudia
  surname: Keller
  fullname: Keller, Claudia
  organization: ETH Zurich
– sequence: 20
  givenname: Markus
  surname: Weber
  fullname: Weber, Markus
  organization: Neuromuscular Diseases Unit/ALS Clinic
– sequence: 21
  givenname: Roger
  surname: Schibli
  fullname: Schibli, Roger
  organization: University Hospital Zurich
– sequence: 22
  givenname: Linjing
  surname: Mu
  fullname: Mu, Linjing
  organization: University Hospital Zurich
– sequence: 23
  givenname: Uwe
  surname: Grether
  fullname: Grether, Uwe
  organization: F. Hoffmann-La Roche
– sequence: 24
  givenname: Simon M.
  orcidid: 0000-0003-4285-6731
  surname: Ametamey
  fullname: Ametamey, Simon M.
  email: simon.ametamey@pharma.ethz.ch
  organization: ETH Zurich
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32787079$$D View this record in MEDLINE/PubMed
BookMark eNqNkstuEzEUhkeoiKaFN0DISyQ6wZe5sqtCC5EqEVVhPTpjn0lczdiD7QnK6_FkOE3aBQtgZcv-vnMs_-ciOTPWYJK8ZXTOKGcfQfr5w4BKbnGYU0lpWVYvkhnLOU2zimZnyYxSzlNecHGeXHj_QCkVjItXybngZVXSsp4lv5YKTdCdlhC0NQSMIiuHstcmHvXkM-6wt-MQIWI7AoRf5VdFunbaT60POkwBFbntJ-u0gcN-tXdaaYNRdXoXq-6QgI_mPShte705tOisI2GLZGW9Di72vRm094cHrO1gNw7G7Z4sB9hoszn0XYAx0GpjtSLr_YiEk3uUOAbr_OvkZQe9xzen9TL5fnuzXnxN7759WS6u71LIWBbSmucykxSglUXOUamSirJQRUtlnbc5bUvWdUzUILoKAQsBImdCFSALBZh34jJ5f6w7OvtjQh-a-GaJfQ8G7eQbnomM5jWr64i-O6FTGyNqRqcHcPvm6d8j8OEI_MTWdl5qNBKfsRhUXuYVizFSykSkq_-nFzo8RrmwkwlRzY6qdNZ7h92zxmhzmKMmzlHzNEfNaY6i9ukPTZ7KBge6_5dMj_LjrZ2cibH8XfkNIzrk2A
CitedBy_id crossref_primary_10_1039_D4SC00402G
crossref_primary_10_1002_cbic_202400704
crossref_primary_10_1021_acs_jmedchem_1c01571
crossref_primary_10_1021_acs_jmedchem_2c01585
crossref_primary_10_1021_acs_jmedchem_2c00256
crossref_primary_10_1021_acs_jmedchem_4c01769
crossref_primary_10_1002_cbic_202300819
crossref_primary_10_1080_13543776_2024_2368745
crossref_primary_10_1021_acsptsci_4c00348
crossref_primary_10_1021_acsptsci_4c00269
crossref_primary_10_1111_bph_15469
crossref_primary_10_1021_acs_jmedchem_4c03127
crossref_primary_10_1021_acs_chemrev_1c00795
crossref_primary_10_1021_acs_jmedchem_3c01035
crossref_primary_10_3390_ph16091235
crossref_primary_10_1021_acschemneuro_3c00345
crossref_primary_10_1016_j_steroids_2022_109112
crossref_primary_10_1007_s11307_021_01655_4
crossref_primary_10_1021_acschemneuro_3c00222
crossref_primary_10_3389_fnagi_2022_1018610
crossref_primary_10_1021_acs_jmedchem_0c01459
crossref_primary_10_1039_D1SC06659E
crossref_primary_10_1016_j_arabjc_2023_105278
crossref_primary_10_1021_acs_jmedchem_4c00465
crossref_primary_10_1053_j_semnuclmed_2023_03_004
crossref_primary_10_1021_acs_jmedchem_1c00913
crossref_primary_10_1124_pharmrev_122_000600
crossref_primary_10_1186_s41181_024_00319_2
crossref_primary_10_1039_D2RA05661E
crossref_primary_10_3390_ijms22158051
Cites_doi 10.1007/s11307-013-0626-y
10.1016/j.cell.2018.12.011
10.1038/ncomms13958
10.1016/j.biopsych.2015.09.009
10.2174/157488912798842278
10.1517/17460441003605098
10.1111/jnc.13716
10.1021/acs.jmedchem.5b00283
10.1097/aco.0000000000000616
10.1186/2191-2858-3-11
10.1021/acs.jmedchem.7b00155
10.1016/j.bmc.2010.05.058
10.3389/fnins.2016.00431
10.1016/j.ejmech.2017.12.097
10.1002/jlcr.3579
10.1021/je049947x
10.1016/j.imbio.2009.04.001
10.1038/346561a0
10.1186/1471-2377-6-12
10.1016/j.ejps.2014.11.003
10.1016/s0006-8993(00)01981-8
10.2174/092986710790980005
10.1021/acs.jmedchem.6b00554
10.1021/ja00297a048
10.1177/0271678x16685105
10.1038/365061a0
10.3389/fnins.2016.00350
10.4103/2152-7806.169561
10.1021/ja01062a046
10.1016/j.vascn.2019.106609
10.1016/j.ejps.2015.08.014
10.1054/plef.2001.0341
10.1093/brain/awp239
10.1124/pr.110.003004
10.1007/s11481-020-09918-7
10.1016/s0969-8043(00)00269-4
10.1189/jlb.3hi1214-584r
10.1002/syn.20450
10.4161/cam.2.4.6749
10.1021/acs.jmedchem.9b01280
10.1016/j.ejps.2014.12.009
10.1016/j.ejphar.2004.05.023
10.1007/s00259-016-3457-7
10.1523/jneurosci.23-35-11136.2003
10.1016/j.beem.2008.09.003
10.1038/sj.bjp.0707493
10.1177/0271678X16685105
10.1189/jlb.3HI1214-584R
10.1097/ACO.0000000000000616
ContentType Journal Article
DBID AAYXX
CITATION
17B
1KM
AOWDO
BLEPL
DTL
EGQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/acs.jmedchem.0c00778
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science - Science Citation Index Expanded - 2020
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Web of Science
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-4804
EndPage 10306
ExternalDocumentID 32787079
000575814800013
10_1021_acs_jmedchem_0c00778
a589317104
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ALS foundation
GroupedDBID ---
-~X
.K2
4.4
55A
5GY
5RE
5VS
6P2
7~N
AABXI
AAHBH
ABJNI
ABMVS
ABOCM
ABQRX
ABTAH
ABUCX
ACGFO
ACGFS
ACJ
ACS
ADHLV
AEESW
AENEX
AFEFF
AGXLV
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
CUPRZ
DU5
EBS
ED~
F5P
GGK
GNL
IH2
IH9
IHE
JG~
L7B
LG6
P2P
ROL
TN5
UI2
VF5
VG9
W1F
WH7
XSW
YQT
YZZ
ZY4
AAYXX
ABBLG
ABLBI
CITATION
17B
1KM
BLEPL
DTL
GROUPED_WOS_WEB_OF_SCIENCE
CGR
CUY
CVF
ECM
EIF
NPM
YIN
7X8
ID FETCH-LOGICAL-a414t-925c4c0aabc652edd70376d6b0c95b50b71ff139a3f8eae63a3513d6ac6dae5f3
IEDL.DBID ACS
ISICitedReferencesCount 32
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000575814800013
ISSN 0022-2623
1520-4804
IngestDate Fri Jul 11 15:40:12 EDT 2025
Wed Feb 19 02:02:32 EST 2025
Fri Aug 29 16:24:55 EDT 2025
Wed Jul 09 18:14:19 EDT 2025
Tue Jul 01 01:09:51 EDT 2025
Thu Apr 24 23:12:42 EDT 2025
Tue Dec 17 03:28:34 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 18
Keywords SYSTEM
PET RADIOLIGANDS
CB2 RECEPTORS
PHARMACOLOGY
HIGH-AFFINITY
IN-VIVO EVALUATION
EXPRESSION
BINDING
DISCOVERY
LIPOPHILICITY
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a414t-925c4c0aabc652edd70376d6b0c95b50b71ff139a3f8eae63a3513d6ac6dae5f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0563-2491
0000-0002-5204-4473
0000-0003-4285-6731
0000-0003-0396-9952
0000-0002-5550-1844
0000-3002-0563-2491
0000-0001-6927-8252
0000-0001-5354-1546
0000-0002-7617-9364
PMID 32787079
PQID 2434059199
PQPubID 23479
PageCount 20
ParticipantIDs pubmed_primary_32787079
webofscience_primary_000575814800013
proquest_miscellaneous_2434059199
webofscience_primary_000575814800013CitationCount
acs_journals_10_1021_acs_jmedchem_0c00778
crossref_primary_10_1021_acs_jmedchem_0c00778
crossref_citationtrail_10_1021_acs_jmedchem_0c00778
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-09-24
PublicationDateYYYYMMDD 2020-09-24
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-24
  day: 24
PublicationDecade 2020
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
– name: United States
PublicationTitle Journal of medicinal chemistry
PublicationTitleAbbrev J MED CHEM
PublicationTitleAlternate J. Med. Chem
PublicationYear 2020
Publisher American Chemical Society
Amer Chemical Soc
Publisher_xml – sequence: 0
  name: American Chemical Society
– name: Amer Chemical Soc
References ref45/cit45
ref3/cit3
ref27/cit27
ref16/cit16
ref23/cit23
ref8/cit8
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref17/cit17
ref10/cit10
ref35/cit35
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
Little P. J. (ref9/cit9) 1988; 247
ref49/cit49
ref13/cit13
ref24/cit24
ref6/cit6
ref36/cit36
Sephton S. M. (ref41/cit41) 2012; 2
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref43/cit43
ref28/cit28
ref40/cit40
ref26/cit26
Piszcz J. A. (ref38/cit38) 2007; 29
ref12/cit12
ref15/cit15
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
Spinelli, F (WOS:000419263400001) 2017; 60
Haider, A (WOS:000505633400015) 2019; 62
Bie, BH (WOS:000454427300004) 2018; 31
Moldovan, RP (WOS:000383111300010) 2016; 59
Houser, SJ (WOS:000085657200042) 2000; 857
MISUMI, A (WOS:A1985AJD7800048) 1985; 107
Sagredo, O. (000575814800013.35) 2012; 7
Wilson, AA (WOS:000166284800003) 2001; 54
Haider, A (WOS:000380313300002) 2016; 10
Palazuelos, J (WOS:000271389300024) 2009; 132
Wagner, B (WOS:000349272000009) 2015; 68
Ahmad, R (WOS:000321972500005) 2013; 15
Rizzo, MD (WOS:000532899200001) 2020; 15
Ahamed, M (WOS:000383765500001) 2016; 10
Pertwee, RG (WOS:000284214900003) 2010; 62
Staiano, RI (WOS:000371891100004) 2016; 99
Zarei, Sara (MEDLINE:26629397) 2015; 6
Li, XT (WOS:000456526100008) 2019; 176
Rieder, SA (WOS:000281048000003) 2010; 215
Dittel, BN (WOS:000252883900011) 2008; 153
Bendels, S (WOS:000493898300002) 2019; 99
Yrjölä, S (WOS:000348257500009) 2015; 67
Haider, A (WOS:000425198200057) 2018; 145
Giboureau, N (WOS:000250356200003) 2007; 61
Pottier, G (WOS:000394660400034) 2017; 37
Pertwee, R. G. (000575814800013.29) 2002; 66
Gómez, M (WOS:000208234100008) 2008; 2
MATSUDA, LA (WOS:A1990DT67900072) 1990; 346
Govaerts, SJ (WOS:000222559200005) 2004; 495
Slavik, R (WOS:000384031400008) 2016; 138
Reggio, PH (WOS:000275937100009) 2010; 17
GAONI, Y (WOS:A19643141B00015) 1964; 86
Benito, C (WOS:000187228500017) 2003; 23
Waring, MJ (WOS:000275939400003) 2010; 5
LITTLE, PJ (WOS:A1988R471000035) 1988; 247
Assmus, F (WOS:000364029500004) 2015; 79
Teodoro, Rodrigo (MEDLINE:24063584) 2013; 3
Soethoudt, M (WOS:000391061700001) 2017; 8
Paschke, A (WOS:000225096000031) 2004; 49
Sephton, SM (WOS:000218871200002) 2012; 2
Yiangou, Y (WOS:000236272700001) 2006; 6
Slavik, R (WOS:000355495200011) 2015; 58
MUNRO, S (WOS:A1993LV64600054) 1993; 365
Alpár, A (WOS:000371577400002) 2016; 79
Spinelli, F (WOS:000428647600015) 2018; 61
Horti, AG (WOS:000279744700038) 2010; 18
Ahmad, R (WOS:000385161100016) 2016; 43
Piszcz, J A (MEDLINE:18004250) 2007; 29
Moreira, FA (WOS:000264631800011) 2009; 23
References_xml – ident: ref20/cit20
  doi: 10.1007/s11307-013-0626-y
– ident: ref32/cit32
  doi: 10.1016/j.cell.2018.12.011
– ident: ref48/cit48
  doi: 10.1038/ncomms13958
– ident: ref5/cit5
  doi: 10.1016/j.biopsych.2015.09.009
– ident: ref15/cit15
  doi: 10.2174/157488912798842278
– ident: ref45/cit45
  doi: 10.1517/17460441003605098
– ident: ref23/cit23
  doi: 10.1111/jnc.13716
– ident: ref42/cit42
  doi: 10.1021/acs.jmedchem.5b00283
– ident: ref17/cit17
  doi: 10.1097/aco.0000000000000616
– ident: ref25/cit25
  doi: 10.1186/2191-2858-3-11
– ident: ref13/cit13
  doi: 10.1021/acs.jmedchem.7b00155
– ident: ref46/cit46
  doi: 10.1016/j.bmc.2010.05.058
– ident: ref26/cit26
  doi: 10.3389/fnins.2016.00431
– ident: ref27/cit27
  doi: 10.1016/j.ejmech.2017.12.097
– ident: ref18/cit18
  doi: 10.1002/jlcr.3579
– ident: ref44/cit44
  doi: 10.1021/je049947x
– ident: ref6/cit6
  doi: 10.1016/j.imbio.2009.04.001
– ident: ref2/cit2
  doi: 10.1038/346561a0
– ident: ref36/cit36
  doi: 10.1186/1471-2377-6-12
– ident: ref24/cit24
  doi: 10.1016/j.ejps.2014.11.003
– ident: ref8/cit8
  doi: 10.1016/s0006-8993(00)01981-8
– ident: ref4/cit4
  doi: 10.2174/092986710790980005
– ident: ref21/cit21
  doi: 10.1021/acs.jmedchem.6b00554
– ident: ref30/cit30
  doi: 10.1021/ja00297a048
– ident: ref22/cit22
  doi: 10.1177/0271678x16685105
– ident: ref3/cit3
  doi: 10.1038/365061a0
– ident: ref28/cit28
  doi: 10.3389/fnins.2016.00350
– ident: ref47/cit47
  doi: 10.4103/2152-7806.169561
– volume: 247
  start-page: 1046
  year: 1988
  ident: ref9/cit9
  publication-title: J. Pharmacol. Exp. Ther.
– ident: ref1/cit1
  doi: 10.1021/ja01062a046
– ident: ref31/cit31
  doi: 10.1016/j.vascn.2019.106609
– ident: ref49/cit49
  doi: 10.1016/j.ejps.2015.08.014
– ident: ref10/cit10
  doi: 10.1054/plef.2001.0341
– ident: ref12/cit12
  doi: 10.1093/brain/awp239
– ident: ref43/cit43
  doi: 10.1124/pr.110.003004
– ident: ref37/cit37
  doi: 10.1007/s11481-020-09918-7
– ident: ref33/cit33
  doi: 10.1016/s0969-8043(00)00269-4
– ident: ref39/cit39
  doi: 10.1189/jlb.3hi1214-584r
– ident: ref40/cit40
  doi: 10.1002/syn.20450
– volume: 2
  start-page: 14
  year: 2012
  ident: ref41/cit41
  publication-title: Am. J. Nucl. Med. Mol. Imaging
– ident: ref7/cit7
  doi: 10.4161/cam.2.4.6749
– ident: ref29/cit29
  doi: 10.1021/acs.jmedchem.9b01280
– ident: ref34/cit34
  doi: 10.1016/j.ejps.2014.12.009
– ident: ref35/cit35
  doi: 10.1016/j.ejphar.2004.05.023
– ident: ref19/cit19
  doi: 10.1007/s00259-016-3457-7
– ident: ref16/cit16
  doi: 10.1523/jneurosci.23-35-11136.2003
– volume: 29
  start-page: 221
  year: 2007
  ident: ref38/cit38
  publication-title: Exp. Oncol.
– ident: ref11/cit11
  doi: 10.1016/j.beem.2008.09.003
– ident: ref14/cit14
  doi: 10.1038/sj.bjp.0707493
– volume: 62
  start-page: 11165
  year: 2019
  ident: WOS:000505633400015
  article-title: Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.9b01280
– volume: 68
  start-page: 68
  year: 2015
  ident: WOS:000349272000009
  article-title: Carrier Mediated Distribution System (CAMDIS): A new approach for the measurement of octanol/water distribution coefficients
  publication-title: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
  doi: 10.1016/j.ejps.2014.12.009
– volume: 15
  start-page: 780
  year: 2020
  ident: WOS:000532899200001
  article-title: Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder
  publication-title: JOURNAL OF NEUROIMMUNE PHARMACOLOGY
  doi: 10.1007/s11481-020-09918-7
– volume: 43
  start-page: 2219
  year: 2016
  ident: WOS:000385161100016
  article-title: Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease
  publication-title: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  doi: 10.1007/s00259-016-3457-7
– volume: 8
  start-page: ARTN 13958
  year: 2017
  ident: WOS:000391061700001
  article-title: Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
  publication-title: NATURE COMMUNICATIONS
  doi: 10.1038/ncomms13958
– volume: 153
  start-page: 271
  year: 2008
  ident: WOS:000252883900011
  article-title: Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
  publication-title: BRITISH JOURNAL OF PHARMACOLOGY
  doi: 10.1038/sj.bjp.0707493
– volume: 10
  start-page: ARTN 350
  year: 2016
  ident: WOS:000380313300002
  article-title: Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging
  publication-title: FRONTIERS IN NEUROSCIENCE
  doi: 10.3389/fnins.2016.00350
– volume: 495
  start-page: 43
  year: 2004
  ident: WOS:000222559200005
  article-title: Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors
  publication-title: EUROPEAN JOURNAL OF PHARMACOLOGY
  doi: 10.1016/j.ejphar.2004.05.023
– volume: 66
  start-page: 121
  year: 2002
  ident: 000575814800013.29
  article-title: Cannabinoid receptors and their 101- ligands. Prostaglandins, Leukotrienes Essent
  publication-title: Fatty Acids
– volume: 37
  start-page: 1163
  year: 2017
  ident: WOS:000394660400034
  article-title: PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats
  publication-title: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
  doi: 10.1177/0271678X16685105
– volume: 346
  start-page: 561
  year: 1990
  ident: WOS:A1990DT67900072
  article-title: STRUCTURE OF A CANNABINOID RECEPTOR AND FUNCTIONAL EXPRESSION OF THE CLONED CDNA
  publication-title: NATURE
– volume: 99
  start-page: ARTN 106609
  year: 2019
  ident: WOS:000493898300002
  article-title: Safety screening in early drug discovery: An optimized assay panel
  publication-title: JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
  doi: 10.1016/j.vascn.2019.106609
– volume: 60
  start-page: 9913
  year: 2017
  ident: WOS:000419263400001
  article-title: Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.7b00155
– volume: 138
  start-page: 874
  year: 2016
  ident: WOS:000384031400008
  article-title: Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2
  publication-title: JOURNAL OF NEUROCHEMISTRY
  doi: 10.1111/jnc.13716
– volume: 5
  start-page: 235
  year: 2010
  ident: WOS:000275939400003
  article-title: Lipophilicity in drug discovery
  publication-title: EXPERT OPINION ON DRUG DISCOVERY
  doi: 10.1517/17460441003605098
– volume: 10
  start-page: ARTN 431
  year: 2016
  ident: WOS:000383765500001
  article-title: Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3
  publication-title: FRONTIERS IN NEUROSCIENCE
  doi: 10.3389/fnins.2016.00431
– volume: 79
  start-page: 27
  year: 2015
  ident: WOS:000364029500004
  article-title: Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates
  publication-title: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
  doi: 10.1016/j.ejps.2015.08.014
– volume: 29
  start-page: 221
  year: 2007
  ident: MEDLINE:18004250
  article-title: Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.
  publication-title: Experimental oncology
– volume: 3
  start-page: 11
  year: 2013
  ident: MEDLINE:24063584
  article-title: Radiofluorination and biological evaluation of N-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB2 receptors.
  publication-title: Organic and medicinal chemistry letters
  doi: 10.1186/2191-2858-3-11
– volume: 6
  start-page: ARTN 12
  year: 2006
  ident: WOS:000236272700001
  article-title: COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord
  publication-title: BMC NEUROLOGY
  doi: 10.1186/1471-2377-6-12
– volume: 86
  start-page: 1646
  year: 1964
  ident: WOS:A19643141B00015
  article-title: ISOLATION, STRUCTURE, AND PARTIAL SYNTHESIS OF AN ACTIVE CONSTITUENT OF HASHISH
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 176
  start-page: 459
  year: 2019
  ident: WOS:000456526100008
  article-title: Crystal Structure of the Human Cannabinoid Receptor CB2
  publication-title: CELL
  doi: 10.1016/j.cell.2018.12.011
– volume: 15
  start-page: 384
  year: 2013
  ident: WOS:000321972500005
  article-title: Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects
  publication-title: MOLECULAR IMAGING AND BIOLOGY
  doi: 10.1007/s11307-013-0626-y
– volume: 2
  start-page: 14
  year: 2012
  ident: WOS:000218871200002
  article-title: Synthesis, radiolabelling and in vitro and in vivo evaluation of a novel fluorinated ABP688 derivative for the PET imaging of metabotropic glutamate receptor subtype 5
  publication-title: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
– volume: 54
  start-page: 203
  year: 2001
  ident: WOS:000166284800003
  article-title: An admonition when measuring the lipophilicity of radiotracers using counting techniques
  publication-title: APPLIED RADIATION AND ISOTOPES
– volume: 17
  start-page: 1468
  year: 2010
  ident: WOS:000275937100009
  article-title: Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown
  publication-title: CURRENT MEDICINAL CHEMISTRY
– volume: 857
  start-page: 337
  year: 2000
  ident: WOS:000085657200042
  article-title: Dynorphin B and spinal analgesia:: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide
  publication-title: BRAIN RESEARCH
– volume: 23
  start-page: 11136
  year: 2003
  ident: WOS:000187228500017
  article-title: Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains
  publication-title: JOURNAL OF NEUROSCIENCE
– volume: 6
  start-page: 171
  year: 2015
  ident: MEDLINE:26629397
  article-title: A comprehensive review of amyotrophic lateral sclerosis.
  publication-title: Surgical neurology international
  doi: 10.4103/2152-7806.169561
– volume: 62
  start-page: 588
  year: 2010
  ident: WOS:000284214900003
  article-title: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
  publication-title: PHARMACOLOGICAL REVIEWS
  doi: 10.1124/pr.110.003004
– volume: 2
  start-page: 246
  year: 2008
  ident: WOS:000208234100008
  article-title: Cannabinoid signaling system Does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis?
  publication-title: CELL ADHESION & MIGRATION
  doi: 10.4161/cam.2.4.6749
– volume: 247
  start-page: 1046
  year: 1988
  ident: WOS:A1988R471000035
  article-title: PHARMACOLOGY AND STEREOSELECTIVITY OF STRUCTURALLY NOVEL CANNABINOIDS IN MICE
  publication-title: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
– volume: 23
  start-page: 133
  year: 2009
  ident: WOS:000264631800011
  article-title: Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
  publication-title: BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
  doi: 10.1016/j.beem.2008.09.003
– volume: 99
  start-page: 531
  year: 2016
  ident: WOS:000371891100004
  article-title: Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors
  publication-title: JOURNAL OF LEUKOCYTE BIOLOGY
  doi: 10.1189/jlb.3HI1214-584R
– volume: 107
  start-page: 3343
  year: 1985
  ident: WOS:A1985AJD7800048
  article-title: SIMPLE ASYMMETRIC CONSTRUCTION OF CARBOCYCLIC FRAMEWORK - DIRECT COUPLING OF DIMENTHYL SUCCINATE WITH 1,OMEGA-DIHALIDES
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 49
  start-page: 1639
  year: 2004
  ident: WOS:000225096000031
  article-title: Octanol/water partition coefficient of selected herbicides:: Determination using shake-flask method and reversed-phase high-performance liquid chromatography
  publication-title: JOURNAL OF CHEMICAL AND ENGINEERING DATA
  doi: 10.1021/je049947x
– volume: 215
  start-page: 598
  year: 2010
  ident: WOS:000281048000003
  article-title: Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression
  publication-title: IMMUNOBIOLOGY
  doi: 10.1016/j.imbio.2009.04.001
– volume: 79
  start-page: E33
  year: 2016
  ident: WOS:000371577400002
  article-title: At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring
  publication-title: BIOLOGICAL PSYCHIATRY
  doi: 10.1016/j.biopsych.2015.09.009
– volume: 61
  start-page: 299
  year: 2018
  ident: WOS:000428647600015
  article-title: Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor
  publication-title: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
  doi: 10.1002/jlcr.3579
– volume: 67
  start-page: 85
  year: 2015
  ident: WOS:000348257500009
  article-title: Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists
  publication-title: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
  doi: 10.1016/j.ejps.2014.11.003
– volume: 61
  start-page: 962
  year: 2007
  ident: WOS:000250356200003
  article-title: Ex vivo and in vivo evaluation of (2R,3R)-5-[18F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter
  publication-title: SYNAPSE
  doi: 10.1002/syn.20450
– volume: 132
  start-page: 3152
  year: 2009
  ident: WOS:000271389300024
  article-title: Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
  publication-title: BRAIN
  doi: 10.1093/brain/awp239
– volume: 59
  start-page: 7840
  year: 2016
  ident: WOS:000383111300010
  article-title: Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.6b00554
– volume: 145
  start-page: 746
  year: 2018
  ident: WOS:000425198200057
  article-title: Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue
  publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1016/j.ejmech.2017.12.097
– volume: 365
  start-page: 61
  year: 1993
  ident: WOS:A1993LV64600054
  article-title: MOLECULAR CHARACTERIZATION OF A PERIPHERAL RECEPTOR FOR CANNABINOIDS
  publication-title: NATURE
– volume: 18
  start-page: 5202
  year: 2010
  ident: WOS:000279744700038
  article-title: Synthesis and biodistribution of [11C] A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY
  doi: 10.1016/j.bmc.2010.05.058
– volume: 7
  start-page: 41
  year: 2012
  ident: 000575814800013.35
  article-title: Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease Recent Pat
  publication-title: CNS Drug Discov
– volume: 31
  start-page: 407
  year: 2018
  ident: WOS:000454427300004
  article-title: An overview of the cannabinoid type 2 receptor system and its therapeutic potential
  publication-title: CURRENT OPINION IN ANESTHESIOLOGY
  doi: 10.1097/ACO.0000000000000616
– volume: 58
  start-page: 4266
  year: 2015
  ident: WOS:000355495200011
  article-title: Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.5b00283
SSID ssj0003123
Score 2.4810576
Snippet Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in...
Source Web of Science
SourceID proquest
pubmed
webofscience
crossref
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 10287
SubjectTerms Animals
Brain - diagnostic imaging
Chemistry, Medicinal
Fluorine Radioisotopes - chemistry
Humans
Life Sciences & Biomedicine
Ligands
Male
Molecular Docking Simulation
Molecular Structure
Pharmacology & Pharmacy
Positron-Emission Tomography
Pyridines - chemical synthesis
Pyridines - pharmacokinetics
Pyridines - pharmacology
Radiopharmaceuticals - chemical synthesis
Radiopharmaceuticals - pharmacokinetics
Radiopharmaceuticals - pharmacology
Rats, Wistar
Receptor, Cannabinoid, CB2 - metabolism
Science & Technology
Spinal Cord - diagnostic imaging
Spleen - diagnostic imaging
Structure-Activity Relationship
Tritium - chemistry
Title Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors
URI http://dx.doi.org/10.1021/acs.jmedchem.0c00778
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000575814800013
https://www.ncbi.nlm.nih.gov/pubmed/32787079
https://www.proquest.com/docview/2434059199
Volume 63
WOS 000575814800013
WOSCitedRecordID wos000575814800013
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZgPMALl3FZuclI0ySkpqvtOE0eUbRqIAERdNLeomPHhrA2mZoUqfw8fhnHubSDgTbeosQnjuPjc75jnwsh-76wiimhPFDc93yplBdFkns-00pwCLUMXKDw-w_B8Yn_7lSebg3FP0_wOTsEXY2-OWfFr2YxGmuXfya8SW7xANexg0Lx543kFYyLPjs4R73eh8r94y1OIenqd4V0CWX-VSE1ymd6j3zsQ3han5Oz0apWI_3jckbHa47rPrnb4VD6pmWcB-SGKXbJ7bgv_7ZLDpI2qfV6SGfbGK1qSA9osk13vX5Ifraxvrbb_KNQZDRBOdqFXNILbkm0tBQoH8ph4M1QuqDQaj0VMjqdr5wrILjrZL3MUaUaJF02xde-GwoVUn6CLC_n-RfXBYJtiuCVJs7rbIn9HuGXu60_OisXXR5u-nbRFGFy_cZQFKDyoswz6oxvyilCZnPuqg09IifTo1l87HWVITzwmV97EZfa12MApQPJTZah3JoEWaDGOpJKjtWEWYvYFoQNDZhAgJBMZAHoIAMjrXhMdoqyMHuEhiFSuW0wY4yfWYCIaRsxYSxaUiHoAXmNM5V2K7tKm0N7ztLmZjd9aTd9AyJ6Vkp1l2LdVfqYX0HlbajO2xQjV7R_1XNpin_WHfBAYcpVlXJfIP6OWBQNyJOWfTdvFNyJ5gk-2b_Iz5vnDrzjiNE6bsyCAWHXaRZ3o3QJFOqn__GrnpE73O1cNOd7z8lOvVyZFwjvavWyWdO_AFKCUDM
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JbtswECXS9JBeuqSbu7JAEKCA5ZqkKEvHwIjhtElgtE6RmzCkqNatLQWWXcD9vH5ZZ7TY6YY0N0HScBFHnEdy5g1je75KjTDKeGCk7_naGC-KtPR8YY2SEFodUKDwyWkwPPPfnuvzLaabWBhsRIElFeUh_oZdQLyhe1_IZ_Gzm3W6lmhowhvsJuIRSYp90P-wnoCVkKohCZdo3puIuX-UQnbJFr_apT_A5l_tUmmDBnfYx3XrS9eTr53lwnTs99-IHa_dvbvsdo1K-UGlRvfYlst22U6_SQa3y_ZHFcX1qs3Hm4itos33-WhDfr26z35Ukb9pvRXIIUv4CGfVOgCTX3JS4nnKgcu2bgfeGOcabHTlt5DwwXRJjoFA16PVfIIG1qHovEzF9s1xKFDyPSSTfDr5RFUg9OYIZfmIfNDmWO8htpw2Avk4n9Ws3PxoVqZkonr7kGVgJlk-STgtxbnkCKDdBeUeesDOBofj_tCr80R44At_4UVSW992AYxFbXBJgrNYL0gC07WRNrpreiJNEemCSkMHLlCgtFBJADZIwOlUPWTbWZ65x4yHIUrRpphzzk9SgEjYNBLKpbiuCsG22Gscqbj-z4u4PMKXIi5v1sMX18PXYqrRqNjWhOuU92N6hZS3lrqoCEeueP9Vo6wxflk67oHM5csilr5CNB6JKGqxR5UWr0tUkibqHj7Zu6zW6-cE5bHHuFYuFwktJv7ntX7dS6JTWDy5xqd6yXaG45Pj-Pjo9N1TdkvSnkZ58veMbS_mS_ccgd_CvCh_85_OvViU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF5BkaAvHOUK5yJVlZDikN21HfuxCo1ajsqCVKp4sfakgcSO4gQp_Dx-GTP2Jg2XCrxZ9s4e3tmd2Z2ZbwjZDYVTTAkVSMXDIIyUCtI04kHItBJcJjqKMVD47XF8eBK-Oo1ON1J9QScqqKmqjfi4qqfGeYQB9gLff0K_xTM76XQ1QtEkl8kVtNwhc-_33683YcG4WAGFcxDxq6i5P9SCsklXP8qmXxTO38qmWg4NbpAP6xHU7iefO4u56uivP4E7_tcQb5LrXjul-w073SKXbLFDrvVXSeF2yF7WQF0v23R4HrlVtekezc5BsJe3ybcmAtj5K0EqC0Mz2F19ICbdcFaipaOS8nbUjoMh7DnQ8cZ_wdDBeIEOghKfs-VsBILWAumsTsn2xVJZAeU7aUblePQRmwAVnIJKSzP0RZtBuwfQc7wQpMNy4tG56dGkTs2E7fZlUUg1KsqRoXgkp5yCIm2nmIPoDjkZHAz7h4HPFxHIkIXzIOWRDnVXSqXjiFtjYDfrxSZWXZ1GKuqqHnMONF4pXGKljYUUERMmljo20kZO3CVbRVnY-4QmCVDh5Zi1NjROypRplzJhHZyvEqlb5DnMVO7Xe5XXpnzO8vqln77cT1-LiBVX5doDr2P-j_EFVMGaatoAj1xQ_tmKYXP4s2j2kYUtF1XOQwFaecrStEXuNZy8rlFw3LB78GV3k7XX31GlhxHDmbk-LLQI-5tifT9KhFWYP_iHX_WUXM1eDvI3R8evH5JtjlcbtQHwEdmazxb2Meh_c_WkXunfAY0VWxc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+Preclinical+Development+of+a+2%2C5%2C6-Trisubstituted+Fluorinated+Pyridine+Derivative+as+a+Radioligand+for+the+Positron+Emission+Tomography+Imaging+of+Cannabinoid+Type+2+Receptors&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Haider%2C+Achi&rft.au=Gobbi%2C+Luca&rft.au=Kretz%2C+Julian&rft.au=Ullmer%2C+Christoph&rft.date=2020-09-24&rft.eissn=1520-4804&rft.volume=63&rft.issue=18&rft.spage=10287&rft_id=info:doi/10.1021%2Facs.jmedchem.0c00778&rft_id=info%3Apmid%2F32787079&rft.externalDocID=32787079
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon